Eledon Pharmaceuticals (ELDN) Earnings Analysis

Eledon Pharmaceuticals (ELDN) next reports earnings on 2026-08-13, consensus EPS -0.19 USD. Last quarter (2026-03-19) it beat with EPS -0.1 USD vs -0.2 USD est (+50%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E -4.28.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ELDN next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.19 USD
Revenue estimaten/a

ELDN earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-19-0.1 USD-0.2 USD+50%Beat
2025-11-14-0.21 USD-0.22 USD+4.5%Beat
2025-08-14-0.13 USD-0.23 USD+43.5%Beat
2025-03-20-0.64 USD-0.32 USD-100%Miss
2024-08-19-0.32 USD-0.31 USD-3.2%Miss

Beat rate: 3/5 (60%) over reported quarters with consensus data.

ELDN valuation and analyst view

Trailing P/E-4.28
Trailing EPS-0.69511 USD
Price / book4.16
Dividend yield0.00%
Market cap0.23B
Analyst consensusBuy (4 buy / 0 hold / 0 sell)
Avg price target5 USD

Related research pages

Frequently asked questions

When is Eledon Pharmaceuticals (ELDN)'s next earnings date?

Eledon Pharmaceuticals is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.19 USD.

Did ELDN beat earnings last quarter?

In its 2026-03-19 report, ELDN posted EPS of -0.1 USD versus a -0.2 USD estimate — a beat of 50%.

What is ELDN's earnings track record?

Over the last 5 reported quarters with consensus data, ELDN beat estimates 3 times (60%).

What is ELDN's current P/E ratio and EPS?

ELDN trades at a trailing P/E of -4.28 on trailing EPS of -0.6951082805464385 USD.

What do analysts rate ELDN?

Analyst consensus is "Buy" across 4 ratings (0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 5 USD.